Several companion compounds like semaglutide with B12 and tirzepatide with B12 have emerged specifically to address this concern
Medications based on semaglutide are currently widely used for the treatment of type 2 diabetes and obesity
The most common adverse reactions reported in clinical trials include nausea, vomiting, diarrhea, abdominal pain, and constipation, occurring in more than 5% of patients
These individuals are not currently eligible for GLP-1 coverage based solely on weight
It also activates the Wnt/beta-catenin signaling pathway, which is critical for follicle development and cycling
494,495,496,497,498 The role of GLP-1 in NASH has garnered attention due to its potential in regulating metabolism, improving insulin sensitivity, and exerting anti-inflammatory effects